Status:
TERMINATED
Study of Brimonidine and Timolol Ophthalmic Solution With Latanoprost Compared With Latanoprost in Glaucoma Patients
Lead Sponsor:
Allergan
Conditions:
Glaucoma, Angle-Closure
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
This study will evaluate the safety and efficacy of patients switched from latanoprost monotherapy to a combination therapy of latanoprost with COMBIGAN® (brimonidine 0.2%/timolol 0.5% fixed combinati...
Eligibility Criteria
Inclusion
- Patient has been administering latanoprost eye drops in affected eye(s) for at least 12 weeks prior to study
- Patient must have at least partially responded to latanoprost and requiring further IOP lowering eye drops
- Diagnosis of chronic angle-closure glaucoma
- Patients using COMBIGAN® in the past must not have been discontinued due to adverse events or lack of efficacy.
Exclusion
- Known allergy or hypersensitivity to COMBIGAN®
- Corneal abnormalities that would preclude accurate IOP readings
- Any other active ocular disease other than glaucoma or ocular hypertension
- Ocular surgery within the past 3 months.
Key Trial Info
Start Date :
November 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2012
Estimated Enrollment :
17 Patients enrolled
Trial Details
Trial ID
NCT01151904
Start Date
November 1 2009
End Date
February 1 2012
Last Update
February 6 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Bangkok, Thailand